Результаты поиска - Hui‐Ling Zhen

  • Отображение 1 - 12 результаты of 12
Отмена результатов
  1. 1
    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib по Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert Newton, Hui‐Ling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C. Burn

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harbori... по Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, Aude Fléchon, Sumati Gupta, Philippe Barthélémy, Michele Maio, Xinhua Zhu, Ekatherine Asatiani, Gul Serbest, Hui‐Ling Zhen, Yohann Loriot

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)

    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGF... по Jason Gotlib, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay Patel, Philomena Colucci, Chris Walker, Hui‐Ling Zhen, Srđan Verstovšek

    Опубликовано 2021
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results по Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Hui‐Ling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

    Опубликовано 2017
    Полный текст Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  5. 5
    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy по Ruben A. Mesa, Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Hui‐Ling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr, Alessandro M. Vannucchi

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom... по Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachée, Mamta Garg, Roger M. Lyons, Steffen Koschmieder, Ciro R. Rinaldi, Jenny Byrne, Yasmin Hasan, Francesco Passamonti, Srđan Verstovšek, Deborah Hunter, Mark M. Jones, Hui‐Ling Zhen, Dany Habr, Bruno Martino

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements по Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan, Mitesh J. Borad, Ghassan K. Abou‐Alfa, Ping Jiang, Christine Lihou, Hui‐Ling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 по Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed MAl Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, E. Van Cutsem, Christine Lihou, Hui‐Ling Zhen, M L Veronese, G.K. Abou-Alfa

    Опубликовано 2024
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) по Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Ghassan K. Abou‐Alfa

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study по Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Tao Ji, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Arndt Vogel

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial по Srđan Verstovšek, A. M. Vannucchi, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, C. N. Harrison, Fabrizio Pane, Pierre Zachée, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, M. Cazzola, Vittorio Rosti, I. Blau, Ruben A. Mesa, Mark M. Jones, Hui‐Ling Zhen, Li J, Nathalie Francillard, Dany Habr, Jean‐Jacques Kiladjian

    Опубликовано 2016
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers по Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij‐de Haas, Gregory Riedlinger, Hua Zhu Ke, Russell W. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Hui‐Ling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte‐Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou‐Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jiménez, Shridar Ganesan, Lodewyk F.A. Wessels, Jos Jonkers

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: